Want to see IN:GUFICBIO full AI Analyst Report?

Gufic Biosciences Limited (GUFICBIO) Price & Analysis

0 Followers

GUFICBIO Stock Chart & Stats

₹338.15

-₹9.05(-1.92%)

At close: Jan 09 4:00 PM EST

₹338.15

-₹9.05(-1.92%)

Day’s Range― - ―

52-Week Range₹267.50 - ₹447.85

Previous CloseN/A

Volume28.80K

Average Volume (3M)2.36K

Market Cap

₹40.78B

Enterprise Value₹40.03B

Total Cash (Recent Filing)₹880.79M

Total Debt (Recent Filing)₹3.69B

Price to Earnings (P/E)63.6

Beta0.64

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.03%

Share Statistics

EPS (TTM)5.68

Shares Outstanding100,282,510

10 Day Avg. Volume2,111

30 Day Avg. Volume2,356

Financial Highlights & Ratios

PEG Ratio-5.32

Price to Book (P/B)4.13

Price to Sales (P/S)2.91

P/FCF Ratio-152.53

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Sterile Injectable & Lyophilized ExpertiseSpecialized sterile injectable and lyophilized manufacturing raises technical barriers to entry and supports higher-value products. This durable capability fosters long-term customer relationships, product differentiation across therapeutic segments, and less commoditized revenue, helping sustain margins and market position.

Healthy Gross And Operating MarginsFY2026 gross (~36%) and operating (~12.8%) margins indicate efficient manufacturing and pricing power. These sustained mid‑teens operating dynamics provide a buffer against input cost swings, support reinvestment and product development, and underpin longer‑term cash generation if operational volatility is controlled.

Manageable Leverage And Positive ROEAn improved debt-to-equity (~0.61) alongside equity growth and positive ROE (~9.7%) signals a more balanced capital structure. Manageable leverage enhances financial flexibility for capex or selective M&A, lowers refinancing pressure versus prior years, and supports medium-term investments without extreme solvency risk.

Bears Say

Severely Weakened Cash GenerationOperating cash flow plunged and free cash flow turned negative in FY2026, showing poor earnings-to-cash conversion and volatile cash generation. This constrains the firm's ability to fund capex, service or reduce debt, and maintain dividends without external financing, increasing financing and execution risk over the medium term.

Declining Net ProfitabilityNet margin compression to ~6.8% and a decline in net income versus the prior year suggest weakening bottom-line conversion. Persistently lower profitability reduces retained earnings, limits internal funding capacity for growth initiatives, and magnifies vulnerability to pricing pressures or cost inflation.

Choppy Revenue And Earnings VolatilityRevenue re-acceleration after a flat year points to uneven top-line performance and episodic demand. Such volatility complicates forecasting and capital allocation, may reflect dependence on intermittent product cycles or contract timing, and raises execution risk for achieving consistent medium-term growth targets.

Gufic Biosciences Limited News

Gufic Biosciences Settles SEBI Compliance Penalties Over Independent Director Appointment

Gufic Biosciences Limited ( ($IN:GUFICBIO) ) has shared an update. Gufic Biosciences has disclosed that stock exchanges BSE...

4M ago

Gufic Biosciences to Appeal GST Penalty Order, Sees No Material Impact

Gufic Biosciences Limited ( ($IN:GUFICBIO) ) has provided an update. Gufic Biosciences Limited has disclosed that it received...

6M ago

Gufic Biosciences Releases Earnings Call Audio

Gufic Biosciences Limited ( ($IN:GUFICBIO) ) has shared an announcement. Gufic Biosciences Limited announced that the audio recording...

8M ago

Gufic Biosciences Schedules Analyst and Investor Meeting

The latest update is out from Gufic Biosciences Limited ( ($IN:GUFICBIO) ). Gufic Biosciences Limited has announced a...

8M ago

GUFICBIO FAQ

What was Gufic Biosciences Limited’s price range in the past 12 months?

Gufic Biosciences Limited lowest stock price was ₹267.50 and its highest was ₹447.85 in the past 12 months.

What is Gufic Biosciences Limited’s market cap?

Gufic Biosciences Limited’s market cap is ₹40.78B.

When is Gufic Biosciences Limited’s upcoming earnings report date?

Gufic Biosciences Limited’s upcoming earnings report date is Aug 06, 2026 which is in 36 days.

How were Gufic Biosciences Limited’s earnings last quarter?

Gufic Biosciences Limited released its earnings results on May 29, 2026. The company reported ₹2.18 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.18.

Is Gufic Biosciences Limited overvalued?

According to Wall Street analysts Gufic Biosciences Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Gufic Biosciences Limited pay dividends?

Gufic Biosciences Limited pays a Annually dividend of ₹0.1 which represents an annual dividend yield of 0.03%. See more information on Gufic Biosciences Limited dividends here

What is Gufic Biosciences Limited’s EPS estimate?

Gufic Biosciences Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Gufic Biosciences Limited have?

Gufic Biosciences Limited has 100,282,510 shares outstanding.

What happened to Gufic Biosciences Limited’s price movement after its last earnings report?

Gufic Biosciences Limited reported an EPS of ₹2.18 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.904%.

Which hedge fund is a major shareholder of Gufic Biosciences Limited?

Currently, no hedge funds are holding shares in IN:GUFICBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Gufic Biosciences Limited

Gufic Biosciences Limited is an Indian enterprise dedicated to the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic medications, and related support services. The company's API and bulk drug offerings include antifungals, anesthetics, immunosuppressants, and intermediates for antifungal treatments. It also produces lyophilized injectable pharmaceuticals, covering diverse therapeutic areas such as antibiotics, antifungals, cardiac care, infertility solutions, antivirals, and proton-pump inhibitors. Additionally, Gufic Biosciences provides pharmaceutical products under its Spark, Criti Care, and Ferti Care brands, as well as a line of herbal and personal care items. The company distributes its extensive product portfolio to hospital networks and medical facilities, and it exports its goods to over twenty countries globally. Established in 1970, Gufic Biosciences Limited is headquartered in Mumbai, India.